Athero Review - Issue 3/2022

Editorial

127
Editorialy

Guidelines

130
Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies

Michal Vrablík, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Jan Piťha, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Zuzana Urbanová Za Výbor Čsat, Jana Mašková


Reviews

140
Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin

Jan Vachek, Kateřina Oulehle, Hana Ciferská, Oskar Zakiyanov, Vladimír Tesař

147
Bempedoic acid – a new drug to lower LDL-cholesterol level

Vladimír Soška, Ondřej Kyselák

152
The importance of diet therapy and the correct regimen in familial hypercholesterolemia

Věra Boháčová, Tamara Starnovská


Clinical Studies

156
PACMAN-AMI trial: review of endpoints

Roman Margóczy

159
What have imaging studies with evolocumab yielded?

Tomáš Kovárník, Karel Kopřiva, Jan Pudil, Zhi Chen, Milan Šonka


Personal News

166
Profesor Zdeněk Zadák pětaosmdesátiletý!

From International Literature

167
Research on remarkable articles from international literature

Eva Tůmová


Announcements

169
XXXVI. konference o hyperlipoproteinemiích – Šobrův den 2022

Kristýna Čillíková


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account